Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Argenx SE ARGX

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.2B
▲ 89.9% YoY
$1.3B
▲ 55.1% YoY
$679.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

argenx SE has established its own sales force in the U.S., Japan, Europe and Canada to commercialize VYVGART for the treatment of gMG and CIDP. It utilizes third-party contract manufacturers that operate in accordance with the FDA's current good manufacturing practices for the manufacture of drug substances and drug products. As of December 31, 2025, it had 1,863 full-time employees, including fully staffed commercial teams in the U.S., Europe, Japan and Canada. VYVGART is approved in more than 30 countries, across three indications and three presentation forms. Its Immunology Innovation Program has over 25 active programs. argenx SE was incorporated under the laws of the Netherlands on April 25, 2008, as a private company with limited liability. On April 26, 2017, it converted to a Dutch European public company with limited liability (Societas Europaea).

Written from the business description in ARGENX SE's annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.

Growth

USD 4.2B
Revenue, FY2025 · full 11-year series below
Revenue $B Net income $B
FY2025 · Revenue 4.2 · Net income 1.3
1.50B3.00B-0.25B-0.50B
20152018202120242025
Compound annual growth
+118.0%
+151.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +151.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

31 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 25.4% · Net 31.1%
-500%-1000%
201520202025
ROE
FY2025 · ROE 20.2%
10%20%-20%-40%
201520202025
Three returns, three denominators.

Each USD of equity produced 20 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 679.0
250.0M500.0M-400.0M-800.0M
201520202025

Total assetsUSD 8.7B
CashUSD 3.5B
Current ratio5.23×

Not available: we don't have the total debt figure for this period.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ARGX, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue $B4.22.21.20.40.50.00.1◌◌◌◌
Operating income $B1.1−0.0−0.4−0.7−0.3−0.5−0.2◌◌◌◌
EBITDA $B◌◌◌◌◌◌◌◌◌◌◌
Income tax $B−0.0−0.7−0.0−0.00.00.00.0◌◌◌◌
Net income $B1.30.8−0.3−0.7−0.4−0.6−0.2◌◌◌◌
Free cash flow $B0.7−0.1−0.4−0.9−0.6−0.40.1−0.1−0.00.0−0.0
EPS, diluted $19.5712.78−5.16−13.05−7.99−13.40−4.69◌◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————
ROE %20.217.4−8.5−26.5−19.4−42.6−20.2−13.9−13.8−42.5−41.1
Shares out B0.060.060.060.060.050.050.040.040.030.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 5 failures in 40 reconciliationsAUDITED

Reconciled in 6 of the 11 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. 15 checks were skipped: cost of revenue is not tagged before 2022. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency5 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image